Skip to main content

Table 1 Summary of the patient characteristics and treatments

From: Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer

Variables No. of patients (%)
or
Median (range)
Sex
 Male 44 (72.1)
 Female 17 (27.9)
Age (years) 62 (32–92)
ECOG performance status before radiotherapy
 < 2 19 (31.1)
 ≥ 2 42 (68.9)
Disease status before radiotherapy
 Locally advanced disease 20 (32.8)
 Combined locally advanced and metastatic disease 41 (67.2)
Pathology
 Tubular adenocarcinoma 56 (91.8)
 Signet ring cell carcinoma 5 (8.2)
Location
 Proximal 10 (16.4)
 Body 25 (41.0)
 Distal 26 (42.6)
Baseline hemoglobin level (g/dL) 7.1 (3.3–10.4)
Initial symptomsa
 Melena 52 (85.2)
 Hematemesis 20 (32.8)
Endoscopic hemostasis before radiotherapy
 Yes 30 (49.2)
 No 31 (50.8)
Angiographic intervention before radiotherapy
 Yes 10 (16.4)
 No 51 (83.6)
Radiotherapy dose (Gy) 30 (12.5–50)
Previous chemotherapy before gastric bleeding
 Yes 50 (82.0)
 No 11 (18.0)
Additional chemotherapy after radiotherapy
 Yes 30 (49.2)
 No 31 (50.8)
  1. ECOG Eastern Cooperative Oncology Group
  2. aPercentages add up to > 100% because 11 patients had both symptoms at initial presentation.